HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Supplement Firms Warned About Offering Menu Of Disease Treatments, Topped By Diabetes

Executive Summary

Three weeks after warning 10 firms, FDA publishes warnings identifying diabetes claims firms in New York and Tennessee; in August, it found so many violative claims by firms in Idaho and Oregon it might have been more efficient to identify diseases their products weren’t promoted to treat.

You may also be interested in...



Hemp Supplement Sales Continue In US Without FDA Acknowledgement As Lawful Products

Decision, explained by Principal Deputy Commissioner Woodcock, turns page on FDA’s 2019 announcement, after hemp was de-scheduled in 2018 farm bill, it would consider rulemaking for lawful use of hemp in supplements.

Improving US FDA Food Programs Starts At Top, Former Senior Agency Officials Say

Former acting commissioner Stephen Ostroff and Sharon Lindan Mayl, previously a senior advisor to FDA commissioner on food programs, say Reagan-Udall report was accurate in finding that establishing food program leadership with defined authorities is key to improving the programs, which include regulation of supplement manufacturing and marketing.

US Consumer Health Industry In 2023: FDA Decision On Lawful Use Of Hemp Top Of Mind

“Right now, it looks like [FDA’s] hands are tied because that's their message … But they're holding both ends of the rope. Come on, get that knot undone,” says AHPA president Michael McGuffin. “To anybody who's looking at this as an outsider, you would say, ‘What is the agency doing?’’ says NPA CEO Daniel Fabricant.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151801

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel